TORONTO, ON / ACCESSWIRE / July 31, 2019 / Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient five, enrolled and treated in the Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 540 day clinical and cystoscopy assessment.

The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment.

The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints at 90 and 180 days, when treated with the Therapeutic Dose.

Patient five has demonstrated no tumour recurrence, progression or presence of NMIBC disease at the 90, 180, 270, 360 and now 540 days post treatment clinical and cystoscopy assessment, marking a new achievement for the Company.

Patient five and six were enrolled and treated in the Study at the Therapeutic Dose (0.70 mg/cm2). Theralase’s Anti-Cancer Treatment involved the intravesical instillation of a water-based solution of Theralase’s lead anti-cancer PDC, TLD-1433, via a catheter inserted through the urethra into the bladder of the patient, to allow the PDC to be preferentially absorbed by NMIBC tumours. The bladder was then drained of the solution, flushed with sterile water to remove non-absorbed solution and refilled with sterile water via a cystoscope. A fibre optic assembly, comprising a Laser Emitter used to emit laser light and a proprietary Dosimetry System used to detect laser light, were then used to activate TLD-1433 resident in the NMIBC tumours.

Shawn Shirazi, Ph.D., Chief Executive Officer – Drug Division of Theralase® stated, “Today, we received additional evidence that even a single treatment with Theralase’s Photo Dynamic Therapy (“PDT”) is able to lead to a duration of Complete Response (“CR”) at 540 days post treatment for patients presenting with Bacillus Calmette Guérin (“BCG”)-Unresponsive NMIBC. This provides further support of the enormous opportunity that awaits Theralase in the treatment of NMIBC. If we are able to obtain similar efficacy results in CR rate and Duration in a larger patient population, through the Phase II NMIBC clinical study, then the Theralase Anti-Cancer Technology has the potential to be the next standard in the treatment of NMIBC. We are extremely excited and encouraged by this recent data demonstrating that BCG-Unresponsive NMIBC patients, who refused or were ineligible to undergo a radical cystectomy (surgical removal of bladder) have remained cancer free at 360 and now up to 540 days post treatment. Theralase’s TLD-1433 Photo Dynamic Therapy (“PDT”) may provide sustainable and comprehensive benefit to people diagnosed with NMIBC and the Company will be providing updates on the Phase II NMIBC clinical study as patients are enrolled and treated. The Theralase Anti-Cancer Technology is also multi-faceted, in that the technology is able to be adapted to the treatment of additional cancer indications if successfully validated in independent clinical studies. The Company plans to investigate the commencement of an additional Phase Ib clinical study for a new cancer indication after the Phase II clinical study is well underway.”

About Theralase Technologies Inc.

Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers.

Additional information is available at www.theralase.com and www.sedar.com.

This news release contains “forward-looking statements” which reflect the current expectations of management of the Company’s future growth, results of operations, performance and business prospects and opportunities. Such statements include, but are not limited to, statements regarding the Company’s proposed development plans with respect to Photo Dynamic Compounds and their drug formulations. Wherever possible, words such as “may“, “would“, “could“, “should”, “will“, “anticipate“, “believe“, “plan“, “expect“, “intend“, “estimate“, “potential for” and similar expressions have been used to identify these forward-looking statements. These statements reflect management’s current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions including with respect to the ability of the Company to: adequately fund, secure the requisite regulatory approvals to commence and successfully complete a Phase II NMIBC clinical study in a timely fashion and implement its development plans. Many factors could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements; including, without limitation, those listed in the filings made by the Company with the Canadian securities regulatory authorities (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements. The Company disclaims any intention or obligation to revise forward-looking statements whether as a result of new information, future developments or otherwise except as required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information:

1.866.THE.LASE (843-5273) x304
416.699.LASE (5273) x304
Amelia Tudo, Investor Relations Coordinator
atudo@theralase.com
www.theralase.com

SOURCE: Theralase® Technologies Inc.

ReleaseID: 554035

ORLANDO, FL / ACCESSWIRE / July 31, 2019 / A recent announcement from High Tide Inc. (HITI.CN) (HITIF) shows real momentum for a Company looking to penetrate the lucrative cannabis arena with separate and diversified revenue lines. Our sister publication recently outlined High Tide’s unique efforts to pair celebrities and pop culture icons with branded cannabis accessories and related goods, but a recent High Tide press release denoting the sale of cannabis through the Company’s Canna Cabana outlets is big news too.

Simply put, High Tide now has a stake in the cannabis retail industry as three MORE Canna Cabana shops all received their first deliveries of cannabis products from Alberta Gaming, Liquor and Cannabis (“AGLC”) and have begun selling recreational cannabis for adult use. The new Alberta Stores bring the total number of Canna Cabana retail locations currently selling recreational cannabis to a total of 14 branded locations across Canada.

Fourteen locations so far is a good size footprint for a relatively young company and a pretty strong indication of the management team’s ability to secure the permission from the government and to rapidly build and scale a nice chain of retail outlets. Obviously, fourteen stores gives the Company a quickly expanding opportunity to monetize cannabis sales, and we’re expecting, introduce their branded products to an ideal audience.

About SmallCap Sentinel:

SmallCap Sentinel is owned and operated by Emerging Markets Consulting (EMC), a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.

For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php

Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.

We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.

EMC has been paid 20,000 dollars on behalf of High Tide for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial. http://emergingmarketsllc.com/disclaimer.php

Emerging Markets Consulting, LLC

Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com

SOURCE: Emerging Markets Report

ReleaseID: 554069

Announcement to The Toronto Stock Exchange and OTCQB

SUBIACO, WESTERN AUSTRALIA / ACCESSWIRE / July 31, 2019 / The Board of RTG Mining Inc. (“RTG”, “the Company”) (ASX:RTG, TSX:RTG, OTCQB:RTGGF) announces that the Company has filed the June 2019 Quarterly Activities Report (“the Report”) to the ASX as required under ASX listing rules.

The Report can be found on the RTG Mining website (www.rtgmining.com) and on the ASX, under announcements (www.asx.com.au).

ABOUT RTG MINING INC

RTG Mining Inc. is a mining and exploration company listed on the main board of the Toronto Stock Exchange, Australian Securities Exchange and the OTCQB Venture Market. RTG is focused on a proposal with a landowner lead consortium to secure an exploration licence at the high tonnage copper-gold Panguna Project in Bougainville PNG and the high grade copper/gold/magnetite Mabilo Project in the Philippines, while also identifying major new projects which will allow the Company to move quickly and safely to production.

RTG has an experienced management team which has to date developed seven mines in five different countries, including being responsible for the development of the Masbate Gold Mine in the Philippines through CGA Mining Limited. RTG has some of the most respected and international institutional investors as shareholders including Franklin Templeton, Sun Valley, Sprott and Equinox.

ENQUIRIES

Australian Contact
President & CEO – Justine Magee

Tel: +61 8 6489 2900
Fax: +61 8 6489 2920
Email: jmagee@rtgmining.com

US Contact
Investor Relations – Jaime Wells

+1 970 640 0611
jwells@rtgmining.com

CAUTIONARY NOTE STATEMENT

This announcement includes certain “forward-looking statements” within the meaning of Canadian and applicable securities legislation. Statement regarding interpretation of exploration results, plans for further exploration and accuracy of mineral resource and mineral reserve estimates and related assumptions and inherent operating risks, are forward-looking statements. Forward-looking statements involve various risks and uncertainties and are based on certain factors and assumptions. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from RTG’s expectations include uncertainties related to fluctuations in gold and other commodity prices and currency exchange rates; uncertainties relating to interpretation of drill results and the geology, continuity and grade of mineral deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the development of RTG’s mineral projects; the need to obtain additional financing to develop RTG’s mineral projects; the possibility of delay in development programs or in construction projects and uncertainty of meeting anticipated program milestones for RTG’s mineral projects and other risks and uncertainties disclosed under the heading “Risk Factors” in RTG’s Annual Information Form for the year ended 31 December 2017 filed with the Canadian securities regulatory authorities on the SEDAR website at sedar.com. The forward‐looking statements made in this announcement relate only to events as of the date on which the statements are made. RTG will not release publicly any revisions or updates to these forward‐looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

SOURCE: RTG Mining Inc.

ReleaseID: 554080

VANCOUVER, BC / ACCESSWIRE / July 31, 2019 / Renaissance Gold Inc. (TSX.V:REN / OTCQB:RNSGF) (“RenGold” or the “Company”) is pleased to announce the commencement of drilling on its Ferguson Mountain Project, under an earn-in agreement with Hochschild Mining plc and its Fat Lizard Project, under an earn-in agreement with OceanaGold Corp. (see NRs dated January 17 and February 20, 2019).

Robert Felder, President and CEO states “We are excited to continue our 2019 drilling campaign in Nevada with new partners and new targets that have never been drilled. Following the drill program recently completed by AngloGold Ashanti on our Silicon Project, these are the second and third of an anticipated eight projects to be drilled this year, continuing RenGold’s significant exposure to upside success through our portfolio approach to exploration.”

The Ferguson Mountain project, Elko County, Nevada is a Carlin-type gold target on a northwest trend of gold occurrences encompassing Nevada Gold Mining’s (Barrick-Newmont JV) Long Canyon mine, the Morgan Pass gold occurrence and the Gold Hill mine in Utah (Figure 1).

Geologic mapping, soil and rock chip geochemical sampling and a recent CSAMT survey have refined our understanding of the structural architecture on the Ferguson Mountain project and a 5-hole, 1525 meter reverse circulation program is underway. The initial drill program will test several targets associated with mapped mineralized structures and newly recognized structures interpreted from the CSAMT and their potential intersection with favorable stratigraphic horizons at depth.

The Fat Lizard project, Nye County, Nevada is a low-sulfidation epithermal target with no historic drilling.

(Figure 2).

Target generation work conducted by RenGold and OceanaGold consisted of geologic mapping, geochemical sampling and a gravity survey. Mapping and sampling has documented the presence of silicified ridges and hydrothermal breccias containing anomalous gold (up to 0.5 g/t) and trace elements (Sb, Te, As, Hg). In addition, observations of alteration and vein textures further support the interpretation of a high-level exposure of a low-sulfidation epithermal system with the potential to host high-grade veins associated with boiling horizons at depth. The current drilling program will test the deeper portions of the system with 1240 meters in 3 core holes.

About Renaissance Gold Inc.

Renaissance Gold Inc. is a western US focused prospect generator utilizing a joint venture business model. RenGold applies the extensive exploration experience and high-end technical skills of its founders and team members to search for and acquire high quality precious metal exploration projects that are then offered for joint venture to industry partners who provide exploration funding. RenGold maintains a large portfolio of gold and silver exploration properties and has entered into over 70 exploration agreements over the past 16 years including those of its predecessor, AuEx Ventures Inc., and those from Kinetic Gold. RenGold’s objective is to place its projects into exploration agreements, testing as many drill targets as possible and providing maximum exposure to success through discovery.

Qualified Person

All technical data disclosed in this press release has been verified by RenGold’s Qualified Person, Robert Felder, M.Sc. and Certified Professional Geologist as recognized by the American Institute of Professional Geologists (AIPG).

By: Robert Felder, President & CEO

For further information, contact:

Robert Felder 775-337-1545 or bfelder@rengold.com
Ronald Parratt 775-337-1545 or rparratt@rengold.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain statements that may be deemed “forward-looking” statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although Renaissance Gold Inc. believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of Renaissance Gold Inc’s management on the date the statements are made. Except as required by law, Renaissance Gold Inc. undertakes no obligation to update these forward-looking statements in the event that management’s beliefs, estimates or opinions, or other factors, should change.

SOURCE: Renaissance Gold Inc.

ReleaseID: 554032

HOUSTON, TX / ACCESSWIRE / July 31, 2019 / Vertex Energy, Inc. (NASDAQ:VTNR, “Vertex” or the “Company”), a leading specialty refiner and marketer of high-purity petroleum-based products, today announced that it will release second quarter 2019 financial results before the market opens on Wednesday, August 7, 2019. A conference call will be held that same day at 9:00 A.M. ET to review the Company’s financial results, discuss recent events and conduct a question-and-answer session.

A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Vertex’s website at www.vertexenergy.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time in order to register, download, and install any necessary audio software.

To participate in the live teleconference:

Domestic Live: 844-369-8770

To listen to a replay of the teleconference, which will be available through August 31, 2019:

Domestic Replay: 877-481-4010
Conference ID: 50785

About Vertex Energy Inc

Houston-based Vertex Energy, Inc. (NASDAQ: VTNR) is a specialty refiner of alternative feedstocks and marketer of high-purity petroleum products. Vertex is one of the largest processors of used motor oil in the U.S., with operations located in Houston and Port Arthur (TX), Marrero (LA), and Columbus (OH). Vertex also has a facility, Myrtle Grove, located on a 41-acre industrial complex along the Gulf Coast in Belle Chasse, LA, with existing hydro-processing and plant infrastructure assets, that include nine million gallons of storage. The Company has built a reputation as a key supplier of Group II+ and Group III base oils to the lubricant manufacturing industry throughout North America. For more information visit www.vertexenergy.com

Cautionary Statement Forward-Looking Statements

This press release may contain forward-looking statements, including information about management’s view of Vertex Energy’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). In particular, when used in the preceding discussion, the words “believes,” “hopes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of Vertex Energy, its divisions and concepts to be materially different than those expressed or implied in such statements. These risk factors and others are included from time to time in documents Vertex Energy files with the Securities and Exchange Commission, including but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks. Other unknown or unpredictable factors also could have material adverse effects on Vertex Energy’s future results. The forward-looking statements included in this press release are made only as of the date hereof. Vertex Energy cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, Vertex Energy undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by Vertex Energy.

Company Contact

Noel Ryan, IRC
720.778.2415
ir@vertexenergy.com

SOURCE: Vertex Energy, Inc.

ReleaseID: 554051

Lab is located in same building as PPD® Laboratories’ Central Lab and will support Asia-Pacific oncology trials

FORT MYERS, FL and WILMINGTON, NC / ACCESSWIRE / July 31, 2019 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetics testing services, and Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), announced the grand opening of a NeoGenomics oncology-focused clinical trials testing lab in the same building as the PPD® Laboratories central lab in Singapore.

NeoGenomics’ Pharmaceutical Services Division has established a track record of rapid growth and is building a global network for clinical trials. After opening and operating a College of American Pathologists (CAP) accredited facility in Rolle, Switzerland since 2017 to service European clinical trials, NeoGenomics prioritized additional expansion into Singapore to service the Asia-Pacific region and allow for global clinical trial placement. NeoGenomics Chairman and Chief Executive Officer, Doug VanOort noted, “Our customers in the Pharmaceutical Services Division are truly global customers who want the ability to place studies wherever they can find the enrollees. They are looking to partner with laboratories that provide great service and high quality, consistent testing across the globe. We’re very excited about our Singapore laboratory and the potential growth opportunity we see within the Asia-Pacific region. This is another milestone in our plan to be a premier global provider of services to the pharmaceutical industry.”

NeoGenomics and PPD formed an alliance in 2018 to provide premier laboratory testing solutions for oncology clinical trials and biomarker research and development. Through the collaboration, NeoGenomics provides a wide range of lab testing services to support PPD Laboratories’ oncology clinical trial activities in North America, Europe and Asia-Pacific. This expansion in Singapore is part of the companies’ established plan to invest in PPD’s existing labs service offerings in China and Singapore. It also augments PPD Laboratories’ offerings of specialized oncology and pathology biomarker testing for biopharmaceutical customers and advances the companies’ initiative to provide an integrated, global solution for complex development programs.

“This expansion of our collaboration with NeoGenomics in Singapore is a critical step in enhancing our pathology and molecular capabilities in the Asia-Pacific region, one of the fastest-growing areas of the world for clinical trials,” said Christopher Fikry, M.D., executive vice president of PPD Laboratories. “Our pharmaceutical and biotech customers who are increasing their clinical trial investments in Asia can depend on us to provide one of the industry’s most comprehensive sets of labs services where they have the greatest need. We look forward to further strengthening our alliance with NeoGenomics and jointly supporting global and regional oncology trials.”

Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers bioanalytical, biomarkers, central lab, GMP and vaccine sciences. NeoGenomics provides one of the most extensive oncology and biomarker-focused testing portfolios in the world to support physicians in the diagnosis and treatment of cancer and to serve pharmaceutical clients in clinical trials and drug development.

Douglas VanOort added, “Our mutual clients are excited about NeoGenomics having the capability to handle testing for their study enrollees across the globe. We are thrilled to expand our collaboration with PPD by providing clients with even greater access to our leading scientific and clinical professionals, as well as best-in-class oncology testing.”

About NeoGenomics, Inc.

NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company’s Pharma Services division serves pharmaceutical clients in clinical trials and drug development.

Headquartered in Fort Myers, FL, NeoGenomics operates CAP-accredited and CLIA-certified laboratories in Ft. Myers and Tampa, Florida; Aliso Viejo, Carlsbad and Fresno California; Houston, Texas; Atlanta, Georgia; Nashville, Tennessee; Rolle, Switzerland; and Singapore. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States, and pharmaceutical firms in Europe and Asia. For additional information about NeoGenomics, visit www.neogenomics.com.

About PPD

PPD is a leading global contract research organization providing comprehensive, integrated drug development, laboratory and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 48 countries and more than 21,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a firm commitment to quality to help clients and partners bend the cost and time curve of drug development and optimize value in delivering life-changing therapies to improve health. For more information, visit www.ppdi.com.

Forward-Looking Statements

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements as the result of NeoGenomics’ ability to continue gaining new customers, offer new types of tests, integrate its acquisition of the Genoptix business and otherwise implement its business plan, as well as additional factors discussed under the heading “Risk Factors” and elsewhere in NeoGenomics’ Annual Report on Form 10-K filed with the SEC on February 26, 2019, amended by a 10K/A filed with the SEC on May 8, 2019. As a result, this press release should be read in conjunction with NeoGenomics’ periodic filings with the SEC. In addition, it is NeoGenomics’ practice to make information about the Company available by posting copies of its Company Overview Presentation from time to time on the Investor Relations section of its website at http://ir.neogenomics.com/.

Forward-looking statements represent NeoGenomics’ estimates only as of the date such statements are made (unless another date is indicated) and should not be relied upon as representing the Company’s estimates as of any subsequent date. While NeoGenomics may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its estimates change.

NeoGenomics Contact

William Bonello
+1 239 690 4238 (w) / +1 239 284 4314 (m)
bill.bonello@neogenomics.com

PPD Contacts

Media:
Randy Buckwalter
+1 919 456 4425
randy.buckwalter@ppdi.com

Investors:
Thomas Wilson
+1 910 558 6423
thomas.wilson@ppdi.com

SOURCE: NeoGenomics, Inc.

ReleaseID: 554042

WALTHAM, MA / ACCESSWIRE / July 31, 2019 / EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has completed randomization of over 25% of the patients required for its corneal wound repair pivotal study using the Ocular Bandage Gel (“OBG”) eye drop.

The pivotal study will enroll and randomize up to 270 patients requiring corneal wound repair following photorefractive keratectomy (“PRK”) surgery. After enrolling, each patient is required to attend a formal screening to determine their suitability for the surgery. If approved, the surgery is scheduled for approximately 2 weeks post the screening visit, after which the patient is randomized into either the OBG or standard-of-care group. The patient is then required to return for 2 weeks of follow-up visits where the success of their randomized treatment is measured.

“We are excited to have hit this next milestone with our corneal wound repair pivotal study,” Stephen From, CEO of EyeGate, stated. “We enrolled our first patient in late June, with the first surgery and randomization occurring in mid-July. We have enrolled well over 25% of the patients, with the majority of them approved for surgery and reaching randomization. We are committed to completing this study as efficiently as possible and are pleased with the progress our team has made. We remain on track for receiving topline results by year-end 2019.”

About EyeGate

EyeGate is a clinical-stage specialty pharmaceutical company focused on developing and commercializing products for treating diseases and disorders of the eye.

EyeGate’s lead product, Ocular Bandage Gel (“OBG”), is based on a modified form of the natural polymer hyaluronic acid, which is a gel that possesses unique properties providing hydration and healing when applied to the ocular surface. EyeGate is in the clinic for two different patient populations: photorefractive keratectomy (“PRK”) surgery to demonstrate corneal wound repair and punctate epitheliopathies (“PE”), which includes dry eye.

The objective of OBG is to re-epithelialize the cornea, reduce the risk of infection, improve symptoms, and improve ocular surface integrity. Often current treatments fall short as they are ineffective in protecting and enabling corneal re-epithelialization.

If EyeGate achieves successful completion of the PRK pivotal study and subsequent FDA approval, EyeGate believes OBG will be the only prescription hyaluronic acid eye drop in the U.S. and the only eye drop in the U.S. approved for the healing of corneal epithelial defects. Additionally, if the clinical trial for patients with PE is successful, EyeGate believes OBG will be the only eye drop in the U.S. approved for the treatment of PE.

EGP-437, EyeGate’s other product, incorporates a reformulated topically active corticosteroid, Dexamethasone Phosphate, that is delivered into the ocular tissues through EyeGate’s proprietary innovative drug delivery system, the EyeGate II Delivery System.

For more information, please visit www.EyeGatePharma.com.

EyeGate Social Media

EyeGate uses its website (www.EyeGatePharma.com), Facebook page (https://www.facebook.com/ EyeGatePharma/), corporate Twitter account (https://twitter.com/EyeGatePharma), and LinkedIn page (https://www.linkedin.com/company/135892/) as channels of distribution of information about EyeGate and its product candidates. Such information may be deemed material information, and EyeGate may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor EyeGate’s website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts. The social media channels that EyeGate intends to use as a means of disclosing the information described above may be updated from time to time as listed on EyeGate’s investor relations website.

Forward-Looking Statements

Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These “forward-looking” statements include statements relating to, among other things, the commercialization efforts and other regulatory or marketing approval efforts pertaining to EyeGate’s products, including EyeGate’s OBG product, its EGP-437 Combination Product, as well as the success thereof, with such approvals or success may not be obtained or achieved on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, certain risk factors described under the heading “Risk Factors” contained in EyeGate’s Annual Report on Form 10-K filed with the SEC on March 1, 2019 or described in EyeGate’s other public filings. EyeGate’s results may also be affected by factors of which EyeGate is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. EyeGate expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

Contact

Joseph Green / Laine Yonker
Edison Advisors for EyeGate Pharmaceuticals
646-653-7030 / 7035
jgreen@edisongroup.com / lyonker@edisongroup.com

SOURCE: EyeGate Pharmaceuticals, Inc.

ReleaseID: 554047

PHOENIX, AZ / ACCESSWIRE / July 31, 2019 / The Stock Day Podcast welcomed United Cannabis Corporation (OTCQB:CNAB) (“the Company”), a biotechnology company dedicated to the advancement of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. President and CEO, Earnie Blackmon, joined Stock Day host Everett Jolly.

Jolly began the interview by noting the Company’s rapidly increasing revenues and asked Blackmon his thoughts on the subject. Blackmon shared that the growing revenues are a reflection of the Company’s talented management team. Currently, the team is dedicated to the development of their products in their new Mead, Colorado facility and bringing them to market.

Jolly followed by asking Blackmon to expand on the Company’s project in Mead. Blackmon explained that the facility in this area has a large capacity for employees and is already creating exceptionally high-quality products. The Company is planning to continue developing this facility to advance it to a full-scale operation.

Jolly then noted that the Company has signed several large contracts in the past few months. Blackmon explained that the contracts came at an opportune time when the Company had both the ability and capacity to take them on. These contracts have been utilized to secure the development of their Mead location, which has become a state-of-the-art facility.

Blackmon then explained that the Company is working to expand their facility locations throughout the country. We are currently in operation or buildout in Colorado, South Carolina, and Tennessee. We are developing deals in Florida and Louisiana.

Jolly then inquired about the Company’s goals going forward. Blackmon shared that the Company is looking into securing the placement of their products in large retailers. “We really want to deliver the best quality medicine at the best possible price for the patient. That entails getting it onto the shelves of these stores.”, stated Blackmon.

To close the interview, Blackmon shared that the Company is currently undervalued and will only continue to grow. He also encouraged listeners that the team behind the Company can be trusted to deliver on their promises to investors.

To hear Ernie Blackmon’s entire interview, follow the link to the podcast here:

https://audioboom.com/posts/7329565-ceo-earnie-blackmon-joins-the-stock-day-podcast-to-discuss-their-worldwide-expansion-plan

Investors Hangout is a proud sponsor of “Stock Day,” and Stock Day Media encourages listeners to visit the company’s message board at https://investorshangout.com/

About United Cannabis Corporation

United Cannabis Corporation is a biotechnology company dedicated to the advancement of cannabinoids for medical applications and is building a platform for designing targeted therapies to increase the quality of life for patients around the world. The Company develops, produces and distributes proprietary cannabis-centric products and technologies, including its patented product brand, Prana Bio Nutrient Medicinals, and has established a strong presence in the hemp-derived CBD market, with a state-of-the-art grow, processing, testing and production facility in Colorado. United Cannabis also licenses its intellectual properties relating to the legalized growth, production, manufacture, marketing, management, utilization and distribution of medical and recreational marijuana and marijuana-infused products. Most importantly, United Cannabis is always driven by its underlying mission to help people in pain.

United Cannabis trades on the OTCQB under the symbol CNAB.

For further information, please visit www.unitedcannabis.us.

To discuss partnership opportunities or learn about our distributor program, contact Tres Walsh (tres@unitedcannabis.us) or (720) 903-4656.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors, created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.

About The “Stock Day” Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE CONTACT:

Stock Day Podcast
602-441-3474

SOURCE: Stock Day Media

ReleaseID: 554058

As the New Study Notes, Cobots Can Perform a Number of Complex Operations as Well as Assist with Tasks that Require Lower Amounts of Skill

ONTARIO, CA / ACCESSWIRE / July 31, 2019 / The founders of Cobot Intelligence, Inc. are pleased to announce that they have just released a new study that looks at how their TechMan Collaborative Robots can help companies improve their production efficiency.

To learn more about Cobot Intelligence and read the results of the interesting study, please visit https://cobotintel.com/guide-to-collaborative-robots-market.

As a spokesperson notes, as a company that specializes in the distribution, servicing and training of Collaborative Robots to a number of clients across Canada and the United States, the team at Cobot Intelligence, Inc. knows how their TechMan Robots (TM Robots) are well-designed to perform a number of tasks.

This knowledge inspired them to create a study that looks at how these TM Robots can allow businesses from a wide range of industries to be more cost effective and efficient.

As the study notes, the synchronized work that Cobots perform along with human employees has led to a huge window of opportunity in the field. For instance, Cobots can perform complex operations like assembly, packaging, sorting, dispensing and other tasks, which will lead to savings in both employee costs and time.

In addition, critical operations are easier to perform with the help of machine aids like Cobots, and there is an improvement of standardization of mechanical and electrical procedures. Finally, the study concluded, low-skilled workers can complete work like vehicle painting, packing and other tasks without a great deal of knowledge or training, thanks to working alongside Cobots.

As the study noted, over the course of the next 5 years, the Collaborative Robot market will see a revenue compound annual growth rate of 51.4 percent.

“By 2027, the revenue from this sector will be approximately $7.5 Billion with a 29 percent share of the entire industrial robot market,” the study noted.

This press release was made on behalf of Cobot Intelligence Inc. by DigitalSEO a Digital Marketing Company in Chennai.

About Cobot Intelligence, Inc.:

Cobot Intelligence Inc. specializes in the distribution, servicing and training of Collaborative Robots to Commercial and Industrial clients in Canada and the United States. Their products such as the TechMan Robot (TM Robot) offer smart-simple-safe solutions to clients with production needs. In addition to their distribution specialist, their factory certified technical team will help train staff and guide them through the implementation process. For more information, please visit https://cobotintel.com.

Cobot Intelligence, Inc.
171 Fenmar Drive
Toronto, Ontario CANADA
M9L 1M7

Contact:

Mr. Vadim
info@cobotintel.com
+1 416 642 1660

SOURCE: Cobot Intelligence, Inc.

ReleaseID: 554062